⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLR News
Allarity Therapeutics, Inc. Common Stock
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
globenewswire.com
ALLR
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
globenewswire.com
ALLR